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Background: Neuroblastoma (NB) is the most common extracranial pediatric solid tumor with a highly variable
clinical course, ranging from spontaneous regression to life-threatening disease. Survival rates for high-risk NB patients
remain disappointingly low despite multimodal treatment. Thus, there is an urgent clinical need for additional
biomarkers to improve risk stratification, treatment management, and survival rates in children with aggressive NB.
Results: Using gene promoter methylation analysis in 48 neuroblastoma tumors with microarray technology, we found
a strong association between survival and gene promoter hypermethylation (P = 0.036). Hypermethylation of 70 genes
significantly differentiated high-risk survivor patients from those who died during follow-up time. Sixteen genes with
relevant roles in cancer biology were further validated in an additional cohort of 83 neuroblastoma tumors by bisulfite
pyrosequencing. High promoter methylation rates of these genes were found in patients with metastatic tumors
(either stage metastatic (M) or metastatic special (MS)), 18 months or older at first diagnosis, MYCN amplification,
relapsed, and dead. Notably, the degree of methylation of retinoblastoma 1 (RB1) and teratocarcinoma-derived growth
factor 1 (TDGF1) predicts event-free and overall survival independently of the established risk factors. In addition, low
RB1 mRNA expression levels associate with poor prognosis suggesting that promoter methylation could contribute to
the transcriptional silencing of this gene in NB.
Conclusions: We found a new epigenetic signature predictive for NB patients’ outcome: the methylation status
of RB1 and TDGF1 associate with poorer survival. This information is useful to assess prognosis and improve
treatment selection.
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Neuroblastoma originates from the sympathico-adrenal
lineage of the neural crest and is the most common ex-
tracranial solid tumor in early childhood. This tumor ex-
hibits contrasting patterns of clinical behavior ranging
from spontaneous remission to rapid tumor progression
and death. Prognosis classically depends on age at diag-
nosis [1], tumor stage [2], MYCN oncogene amplification
status [3,4], and histology in a lesser extent [5]. Several
well-characterized genetic abnormalities associated with
neuroblastoma (NB) have been used to predict outcome,
for example, DNA content [6], gain of chromosome arm
17q [7], or deletion of chromosome arm 1p [8] and 11q* Correspondence: yanyez_yan@gva.es
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unless otherwise stated.[9,10]. However, current knowledge of the molecular fea-
tures of NB is not sufficient to explain the observed clin-
ical heterogeneity.
There is an important body of work on NB to find ro-
bust biomarkers that could help to improve the standard
response criteria and, consequently, patients’ survival. In
this regard, several mRNA and miRNA classifiers have
been established [11-13]. A recent study from SIOPEN
shows that levels of tyrosine hydroxylase (TH) and paired-
like homeobox 2B (PHOX2B) or doublecortin (DCX)
mRNA in peripheral blood and bone marrow at diagnosis
are independent predictors of survival [14]. Notably, high
levels of TH and PHOX2B mRNA in peripheral blood
identify ultrahigh-risk NB patients. Despite these new dis-
coveries, survival rates in children with high-risk NB re-
main disappointingly low.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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the 5′ position of cytosines, within CpGs dinucleotides at
gene promoter regions, are essential regulatory mechanisms
for normal cell development and may modulate gene ex-
pression without altering the DNA sequence. In the last
decade, DNA-methylation studies have focused on identi-
fying epigenetically modified genes to further understand
NB pathogenesis and to find prognostic methylation
markers. In this regard, global methylation studies have
demonstrated that a methylator phenotype, characterized
by the methylation of multiple CpG islands, is a hallmark
of NB with poor prognosis [15]. Several tumor suppressor
genes such as caspase 8 (CASP8), Ras association (RalGDS/
AF-6) domain family member 1 (RASSF1A), cycling D2
(CCND2), CD44, O-6-methylguanine-DNA methyltrans-
ferase (MGMT), and PYD and CARD domain containing
(TMS1), have been shown to be silenced in NB by aber-
rant hypermethylation of their promoters [16-18]. In gen-
eral, screening studies in NB showed that frequently
methylated genes are related to apoptotic pathways as well
as to cell cycle regulation.
Recent studies in oncology research have increased gen-
ome coverage allowing the identification of new epigenetic
biomarkers. In NB, two recent studies have investigated
DNA methylation patterns using genome-wide technolo-
gies [19,20]. However, the number of clinically relevant
epigenetic biomarkers is still very low. In here, we used
methylation microarrays to identify robust and independ-
ent epigenetic biomarkers in NB.
Results
Genome-wide promoter methylation screening
With the purpose of identifying DNA methylation bio-
markers, we first analyzed 48 primary NB tumors using
the Infinium HumanMethylation27 BeadChip micro-
array. Clinical, biological, and follow-up data are sum-
marized in Table 1. Patients were classified following the
International Neuroblastoma Risk Group Staging System
(INRGSS) guidelines as 10 L1 (stage 1 localized); 16 L2
(stage 2 localized), 18 M (metastatic), and 4 MS (meta-
static special). Twenty patients relapsed: 1 L1 presented
a local relapse and is alive and disease free, 7 L2 (5 pre-
sented local relapses, 1 metastatic and 1 combined, 4 of
them died of disease); 11 M stages (2 presented local re-
lapses, 3 presented metastatic relapses and 6 combined
relapses, all of them died of disease). One MS stage pre-
sented a metastatic relapse and died due to disease
progression.
Data distribution according to the methylation probe in-
tensity from the Illumina array was shown to be bimodal
(Figure 1A). Using minAS, a method for feature selection
in multivariate data, cutoff values for data discretization
were defined as follows: ≤0.3 hypomethylated ‘0’, >0.3 < 0.7
intermediate ‘0.5’, and >0.7 hypermethylated ‘1’.In order to understand to which extent gene promoter
methylation is relevant to NB, we analyzed differences in
the methylation levels among different patient subgroups.
The most striking result of this analysis revealed a signifi-
cant association between poor survival and global gene
promoter hypermethylation (P = 0.036) (Figure 1B). Pa-
tients who died during follow-up time had higher pro-
moter hypermethylation rates than survivors (median
follow-up time for survivors of 12 years). No association
was detected between survival and global hypomethylation
of gene promoters. Other types of subgrouping (by age at
diagnosis, MYCN status, or relapse) did not reveal any sig-
nificant changes. However, comparing patients at different
NB stages (L1 and MS vs. L2 vs. M) did indicate a near-
significant hypermethylation of the runt-related tran-
scription factor 3 (RUNX3) gene (P = 0.05). These results
suggest that the overall promoter hypermethylation status
at diagnosis could predict survival and that NB stages can
be associated with methylation changes at specific genes.
After establishing a significant association between
promoter hypermethylation and NB, we then aimed to
identify particular methylation events. Comparison of
methylation values of high-risk patients who died of dis-
ease, and of high-risk patients who survived, revealed 70
genes that significantly differentiate these two groups
(Figure 1C and Table 2). Interestingly, only specific CpG
sites within promoter regions were methylated (compare
total probes vs. significative probes that were methylated
on Table 2 and see the scheme on Additional file 1). This
result revealed the importance of sufficient CpG probes at
promoter regions to capture the dynamics of methylation
changes. Sixteen genes with high impact on cancer biology
were selected for validation. The methylated probes and
P values as well as the methylation level of the selected
hypermethylated genes are shown in Table 3. Detailed in-
formation of these genes’ promoter methylation sites in
each patient is described in Additional file 2. These genes
regulate the following: maturation and maintenance of
the overall structure of the nervous system (neuronatin
(NNAT)); cell cycle progression (cyclin D1 (CCND1),
janus kinase 2 (JAK2), retinoblastoma 1 (RB1), leucine-rich
repeat C4 protein (LRRC4), and tumor protein P73 (TP73));
cell growth and differentiation (dual specificity phosphat-
ase 2 (DUSP2), paired box 8 (PAX8), and hepsin (HPN));
tumorigenesis (melanoma antigen family A, 2 (MAGEA2),
RUNX3, cathepsin Z (CTSZ), teratocarcinoma-derived
growth factor 1 (TDGF1), and tetraspanin 32 (TSPAN32));
apoptosis (JAK2 and esophageal cancer-related gene 4
protein (ECRG4)) and DNA repair mechanisms (MGMT).
Validation of the prognostic power of DNA methylation
biomarkers by bisulfite pyrosequencing
To validate the specific CpG methylated sites, we per-
formed sequencing analysis of the 16 promoter genes.
Table 1 Clinical and biological data from the 48 patients included in the microarray analysis
INRG staging system
Characteristics L1 L2 M MS Total
Number of patients 10 16 18 4 48
Pre-treatment risk group
Very low + low 10 2 0 3 15
Intermediate 0 10 2 0 12
High 0 4 16 1 21
Age at diagnostic in months
Median 11.1 18.6 27.6 4 16.1
Range 1.5-22.7 4.8-109.3 6.6-79.8 1.9-6.7 1.5-109.3
Patients over 18 months at diagnostic 4 9 11 0 24
Sex
Female 6 8 6 2 22
Male 4 8 12 2 26
Primary site
Adrenal 1 5 9 3 18
Abdominal 4 5 2 0 11
Cervical 0 1 0 1 2
Thoracic 2 0 4 0 6
Cervical-thoracic 0 1 0 0 1
Thoracic-abdominal 1 1 0 0 2
Pelvic 1 0 0 0 1
Other sites 1 3 3 0 7
Protocol of treatment
LNESG I 2 0 0 0 2
LNESG II 1 0 0 0 1
EUNS 0 2 0 0 2
INES 3 5 2 2 12
HR-NBL-1 0 4 9 0 13
Other (national protocols) 4 4 7 2 17
MYCN status
Amplified (%) 0 (0%) 4 (25%) 8 (44%) 1 (25%) 13 (27%)
Not amplified (%) 10 (100%) 12 (75%) 10 (56%) 3 (75%) 35 (73)
1p status
Normal (%) 8 (80%) 8 (50%) 8 (44%) 3 (75%) 27 (56%)
Deleted (%) 0 (0%) 4 (25%) 7 (39%) 0 (0%) 11 (23%)
Not determined (%) 2 (20%) 4 (25%) 3 (17%) 1 (25%) 10 (21%)
Patients with relapse (%) 1 (10%) 7 (44%) 11 (61%) 1 (25%) 20 (42%)
Type of relapse
Local 1 5 2 0 8
Metastatic 0 1 3 1 5
Local + metastatic 0 1 6 0 7
Dead (%) 0 (0%) 5 (32%) 12 (67%) 1 (25%) 18 (38%)
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Table 1 Clinical and biological data from the 48 patients included in the microarray analysis (Continued)
Cause of death
Disease progression 0 4 11 1 16
Other 0 1 1 0 2
Time of follow-up (month)
Median 152.1 93.5 45.4 129.3 117.4
Range 87.8-208.3 9.4-206.5 3.4-161.2 17.2-214.9 3.4-214.9
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signed flanking the methylated CpG sites detected in the
array. Validation of results was carried out with an inde-
pendent cohort of 83 NB including 12 L1, 21 L2, 42 M,
and 8 MS stages. Clinical and biological data from the
validation cohort is summarized in Table 4.
We performed a multivariate analysis of variance
(MANOVA) statistical analysis in order to study the methy-
lation variations of selected genes among the established
subgroups (see below and “Methods” section) of NB
patients. Overall, we found significantly higher gene pro-
moter methylation rates in patients with the following
characteristics: metastatic tumors (either stage M or MS)Figure 1 DNA promoter methylation profiling from 48 NB primary tum
between gene promoter hypermethylation and patients’ status. (C) Heat map
differentially methylated in the cohort of 48 NB patients.(Figure 2A), aged 18 months or older at first diagnosis
(Figure 2B) and MYCN amplification (Figure 2C). The
same applies to patients who relapsed or died (Figure 2D).
In particular, methylated status of TDGF1 and PAX8
allowed us to differentiate all the clinical subgroups
mentioned above (Figure 2). In addition, high methyla-
tion rates of RUNX3, ECRG4, CTSZ, and RB1 also distin-
guished all NB subgroups but not MYCN-amplified status
(Figure 2). We also found highest methylation rates of
LRRC4 and CCND1 in patients older than 18 months
(Figure 2B). Furthermore, DUSP2, TP73, JAK2, MGMT,
and HPN methylation rates were significantly higher in
MYCN-amplified patients than in non-amplified patientsors. (A) Data distribution according to the probe intensity. (B) Association
representation of DNA promoter methylation data of the 70 genes
Table 2 Seventy significantly hypermethylated genes in high-risk NB patients
Genes Total probes Sig. probes ID. Sig. probes P values
ANKRD30A 2 1 cg18493238 0.044554738
AYTL2 2 1 cg05365670 0.035713814
C14orf162 2 1 cg14912575 0.005363655
C1orf177 2 1 cg20903926 0.012915253
CCND1 18 2 cg11802013, cg07339327 0.0341943541, 0.047611226
CD164L2 2 1 cg15166089 0.021147357
CD3Z 1 1 cg09554443 0.018393493
CDH20 1 1 cg18509435 0.047064214
CGB1 2 1 cg17164520 0.020905647
CNNM1 2 1 cg15430659 0.020905647
CPZ 2 1 cg03292388 0.022686711
CRYAA 2 1 cg19378039 0.004448711
CSH1 2 1 cg11880211 0.035724213
CSMD2 2 1 cg05382123 0.035713814
CTSZ 7 1 cg01663968 0.037116693
DUSP2 2 1 cg01148741 0.012020747
ECRG4 2 1 cg10885338 0.004398444
ENTPD3 2 1 cg17200465 0.022686711
FLJ21736 2 1 cg09407859 0.039315449
FLJ30313 2 1 cg11682508 0.035713814
FLJ39822 2 1 cg04143809 0.047611226
FUT6 2 1 cg05444024 0.03549584
GBGT1 2 1 cg01169778 0.037116693
GDPD2 2 1 cg08254263 0.034194354
GGT6 2 1 cg22628873 0.010030882
GNGT2 2 2 cg17839611, cg24456340 0.0135039944, 0.0183934926
GPR1 1 1 cg19132372 0.047064214
GPR55 2 2 cg20287234, cg13531460 0.005474794, 0.0343533092
HIST1H1A 2 1 cg14652095 0.021147357
HOXB1 2 1 cg17233506 0.020905647
HPN 2 1 cg24715735 0.022686711
JAK2 1 1 cg20394284 0.035713814
KCNQ1 23 1 cg01734338 0.034194354
KRT5 2 2 cg23645091, cg04254916 0.0067809343, 0.0072736595
KRTHB3 2 1 cg19258973 0.012020747
KRTHB5 2 1 cg06132342 0.000549806
KRTHB6 2 2 cg04123507, cg16911220 0.000926591, 0.0053636552
LAT1-3TM 1 1 cg19889584 0.013503994
LOC161931 2 1 cg17561452 0.044554738
LRRC4 2 1 cg21129531 0.013503994
LY6D 2 1 cg05800321 0.032446014
MAGEA2 2 1 cg01743008 0.034353309
MGC35169 2 1 cg16384137 0.021877651
MGMT 26 1 cg02330106 0.031115525
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Table 2 Seventy significantly hypermethylated genes in high-risk NB patients (Continued)
MKNK2 2 1 cg21030400 0.031115525
MSH4 2 1 cg22035229 0.044554738
MUC5B 2 1 cg22407504 0.030056033
NNAT 7 3 cg22510412, cg12862537, cg21588305 0.0182304654, 0.0211473571, 0.0324460138
PADI3 2 1 cg01459162 0.010896145
PAX8 2 1 cg25042226 0.007819456
PECAM1 2 1 cg03886110 0.021147357
PIP5K2A 2 1 cg26368842 0.047611226
PLA2G12B 2 1 cg21820890 0.015211786
POLR3H 1 1 cg02738086 0.044554738
PSCD4 2 1 cg05259765 0.012683212
PTGER1 2 1 cg10468702 0.022686711
PTGIR 2 1 cg11822964 0.035713814
RB1 21 1 cg07880715 0.047611226
RUNX3 19 2 cg04757093, cg25178645 0.0004487598, 0.0390263555
SCNN1A 2 1 cg18738906 0.044000585
SMPX 2 1 cg05856884 0.035713814
SPO11 2 1 cg13888886 0.001023813
TBX4 2 1 cg03866607 0.006780934
TDGF1 2 1 cg10242476 0.037116693
THEG 1 1 cg27227797 0.030056033
TP73 12 3 cg03846767, cg26208930, cg25115460 0.0038887033, 0.0324460138, 0.0470642136
TPM1 2 1 cg00520135 0.007819456
TRIP10 2 1 cg02085507 0.037116693
TSPAN32 2 1 cg00041575 0.007819456
ZNF80 2 1 cg13334054 0.012599325
Yáñez et al. Clinical Epigenetics  (2015) 7:16 Page 6 of 14(Figure 2C). These results demonstrate that these set of
methylated gene promoters allow the discrimination of
specific NB subgroups defined in Figure 2.
To study the influence of the degree of the 16 vali-
dated genes’ promoter methylation on survival, we eval-
uated them as independent prognostic variables by the
elastic net penalized Cox’s regression model. Higher gene
promoter methylation rates of RB1, PAX8, and TDGF1
remained as independent predictors of overall survival
(OS) after adjusting for known prognostic factors
(Table 5A). On the other hand, RB1 and TDGF1 but not
PAX8 predicted worse event-free survival (EFS) (Table 5B).
Information of TDGF1 and RB1 promoter methylation
sites in the validation cohort of patients is described
in Additional file 3. These regressions also confirmed the
well-established stage, MYCN status, and age as independ-
ent predictors, thus further supporting the consistency of
this model. The penalized coefficient of each independent
variable directly associates with survival. Thus, MYCN
amplification and staging have the highest influence on
survival followed by the degree of TDGF1 and RB1promoter methylation. Age at diagnosis had a lower im-
pact in EFS and none in OS.
RB1 expression in NB correlates with survival
Taking into account that RB1 and TDGF1 promoter
methylation is one of the mechanisms responsible for the
downregulation of these genes in other tumors [21,22], we
explored RB1 and TDGF1 expression in NB, the two only
independent predictors of EFS and OS that we found in
this study. For this purpose, we analyzed a new cohort of
251 NB patients using the R2: microarray analysis and
visualization platform (http://r2.arnc.nl). The results of
this analysis are displayed in Figure 3. The Kaplan-Meier
plots show the significant association between low expres-
sion levels of RB1 and poorer outcome (Figure 3A). Based
on these findings, promoter methylation could contribute
to the transcriptional silencing of RB1 in NB. On the other
hand, low expression levels of TDGF1 associates with bet-
ter outcome in this patient cohort (Figure 3B). Since our
results show that high methylation levels of TDGF1 nega-
tively affect patient survival, the TDGF1 expression-
Table 3 Hypermethylated genes selected for pyrosequencing validation
Genes Sign. probes Total probes P values Gene function
NNAT 3 7 0.018, 0.021, 0.032 Involved in the maturation or maintenance of the overall structure of the nervous system
TP73 3 12 0.004, 0.032, 0.047 Participates in the apoptotic response to DNA damage
CCND1 2 18 0.034, 0.048 Essential for the control of the cell cycle at the G1/S (start) transition
RUNX3 2 19 0.0004, 0.039 Tumor suppressor gene
CTSZ 1 7 0.037 May be involved in tumorigenesis and metastasis
DUSP2 1 2 0.012 Regulates cellular proliferation and differentiation
HPN 1 2 0.023 Plays an essential role in cell growth and maintenance of cell morphology
JAK2 1 1 0.036 Involved in cell cycle progression, apoptosis, mitotic recombination, genetic instability,
and histone modifications
LRRC4 1 2 0.014 Significantly downregulated in primary brain tumors. The exact function of the protein
encoded is unknown
MAGEA2 1 2 0.034 May play a role in embryonal development and tumor transformation or aspects of
tumor progression
MGMT 1 26 0.031 Involved in DNA repair mechanisms
PAX8 1 2 0.008 Transcription factor. Mutations in this gene are associated with carcinogenesis
ECRG4 1 2 0.004 Antiapoptotic gene
RB1 1 21 0.048 Negative regulator of the cell cycle
TDGF1 1 2 0.037 Plays an essential role in embryonic development and tumor growth
TSPAN32 1 2 0.008 Is one of several tumor-suppressing subtransferable fragments located in the imprinted
gene domain of chromosome 11p15.5
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event on cg10242476 is not involved in TDGF1 down-
regulation but rather in its expression. In order to investi-
gate the positive correlation between CpG methylation
and TDGF1 expression, we explored the correlation be-
tween TDGF1 expression and the DNA methyltransfer-
ases DNMT1, DNMT3A, and DNMT3B. As shown in
Additional file 4, we found a significant correlation be-
tween TDGF1 and DNMT1 and DNMT3B but not be-
tween TDGF1 and DNMT3A in the cohort of patients
with MYCN amplification. These correlations furtherTable 4 Clinical and biological characteristics of the NB cohor
INRG staging system
Characteristics L1 L2
Number of patients 12 21





Amplified (%) 0 8
Not amplified (%) 12 (100%) 13
Not determined (%) 0 0
Patients with relapse (%) 3 (25%) 5
Dead (%) 0 6support that DNA methylation might as well be impli-
cated in the upregulation of TDGF1 expression.
Discussion
Most of the DNA methylation studies in NB are experi-
mentally limited because they used previously selected
candidate genes based on their implication in cancer de-
velopment or tumor biology [16,23-25]. A recent report
described the signature of hypomethylated regions within
non-promoter regulatory sites [20], thus complementing






(38%) 16 (38%) 1 (12.5%) 25 (30%)
(62%) 23 (55%) 7 (87.5%) 55 (66%)
3 (7%) 0 3 (4%)
(24%) 22 (52%) 0 30 (36%)
(29%) 25 (60%) 0 31 (37%)
Figure 2 Difference in methylation status of indicated genes (% units) among clinical variables in NB patients. Global P value tests the
hypothesis of equal methylation status in both groups. (A) Stages M - MS vs. L1-L2. (B) Patients younger than 18 months at diagnosis vs. patients
older than 18 months at diagnosis. (C) MYCN-amplified patients vs. patients with no-MYCN amplification. (D) Patients with events (relapse/death)
vs. patients without events.
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modeling events that could contribute to the generation
of chromosomal instability. Another recent genome-wide
study has proposed new epigenetic biomarkers of interest
in NB patients [19,26]. However, authors only used cell
lines in the selection phase of potential prognostic DNA
methylation biomarkers. Although candidate genes were
further validated in 89 primary tumor samples, this ap-
proach may have skipped many candidate biomarkersoccurring on primary tumors due to the passage-dependent
epigenetic changes on cell lines. Lau et al. applied a genome-
wide screen of DNA methylation changes using NB pri-
mary tumors [26]. In their study, they pre-selected
candidate genes which may resulted in the loss of novel epi-
genetic biomarkers. In here, we adopted a non-targeted ap-
proach based on genome-wide screen of DNA-methylation
changes. Our results reveal 70 candidate genes that showed
epigenetic changes within the high-risk group. We further















Non-zero coefficients after elastic net penalization. Negative coefficients stand
for variables lowering risk and positive coefficients for variables increasing risk.
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validation studies the remaining group.
The two patient cohorts used in this study included a
representative distribution of all the INRG-based NB sub-
groups, being among the highest and well-characterized
NB cohorts used for genome-wide epigenetic studies so far
reported to our knowledge. Interestingly, the degree of
methylation of the proposed biomarkers is able to distin-
guish between different subgroups of NB: patients who
were older than 18 months at diagnosis from younger than
18 months at diagnosis, patients with MYCN-amplified tu-
mors from MYCN non-amplified tumors, patients with
metastatic tumors from localized tumors and relapsed or
dead patients from relapse-free survivors. These findings
support the idea that aberrant DNA methylation could be
related to NB pathogenesis. Notably, only RB1 and TDGF1
remained as independent prognostic predictors of poorer
OS and EFS. Therefore, our predictive epigenetic bio-
markers constitute a new set of robust risk predictors of
the disease.
TDGF1 promoter is hypomethylated and highly expressed
in human-induced pluripotent stem (iPS) and embryonic
stem (ES) cells [27]. Using the same Illumina array, our re-
sults reveal a different CpG site not only localized down-
stream but also within the first exon (5′-UTR) of TDGF1
gene (cg10242476) that significantly predicts EFS and OS
in NB patients. Importantly, TDGF1 has been shown to
be regulated by the ES cell-related transcription factors
Oct4/Nanog and to a lesser extent by the DNA methyla-
tion status of the promoter region [28]. TDGF1 has been
found overexpressed in a variety of human tumors such as
breast, colorectal, and gastric cancers, and high expression
levels of this gene are associated with poorer prognosis in
those tumors [29]. Using the microarray analysis andvisualization platform R2 (http://r2.arnc.nl), we confirmed
that high TDGF1 expression levels are also associated with
poor prognosis in NB (Figure 3B). Following this reason-
ing, higher methylation of this CpG would correlate with
higher TDGF1 expression and, therefore, with poorer
prognosis. Interestingly, this CpG site is localized in the
first exon of TDGF1 transcript variant 1 (NM_003212)
and coincides with the first intron of TDGF1 transcript
variant 2 (NM_001174136). One plausible explanation for
this correlation is that intronic CpG methylation results in
TDGF1 transcript variant 2 expression. In this regard,
regulation of imprinted IGF2R expression is mediated
by methylation of an intronic CpG island [30]. Taken
all together, these results suggest that intronic CpG
(cg10242476) methylation in TDGF1 transcript variant
2 positively regulates its expression in NB whereas CpG
(cg27371741) hypomethylation in the first exon of TDGF1
transcript variant 1 regulates its expression in embryonic
stem cells. The strong association between hypermethyla-
tion and poor prognosis reflects the consequences of epi-
genetic changes occurring in high-risk NB.
Loss of RB1 expression is associated with a higher grade
of malignancies and seems to be a prognostic indicator in
a variety of human tumors [31,32]. Hypermethylation of
RB1 CpG island is a common epigenetic event associated
with the development of malignant nervous system tumors
[22]. A clear correlation between loss of RB1 expression
and promoter hypermethylation was found in glioblast-
omas [32]. Although hypermethylation of RB1 promoter
has previously been reported in NB, no association with
patient survival was included in the study [33]. Moreover,
the methylation-specific PCR approach used to detect RB1
promoter methylation does not allow to study the broad
CpG sites analyzed with a genome-wide approach. We de-
scribe for the first time that the degree of RB1 promoter
methylation associates with poorer prognosis in NB pa-
tients. In agreement with our findings, using the publicly
available R2 platform, we found that low expression levels
of RB1 associates with poorer outcome. These results
suggest that RB1 promoter methylation could contrib-
ute to its silencing and enhance NB development and
aggressiveness.
Conclusions
Biomarkers are playing an increasing role in the man-
agement of NB patients and, together with drug targets,
represent the future analytical platforms for personalized
clinical intervention. In this work, we demonstrate that
high promoter methylation rates of TDGF1 and RB1 genes
are independent predictive biomarkers of NB aggressive-
ness and disease progression. Our findings highlight the
use of methylation profiling to identify risk-independent
prognostic markers in NB and reinforce the connection
between epigenetic events and NB biology. Taking into
Figure 3 Results of the analysis of a new cohort of 251 NB patients using the R2. Expression graphs (on the right) and Kaplan-Meier plots
(on the left) for RB1 (A) and TDGF1 (B) obtained using the R2: microarray analysis and visualization platform in a cohort of 251 NB patients.
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Table 6 Sequences of primers used for pyrosequencing validation
Genes Amplification primers Sequencing primers
Name Sequence
CTSZ Forward GTTGGGGYGTAGGTGGGTAT GTAGTTTTGGGGGGA
Reverse [Btn]CACAAACATCAAAACTCACCCTAAATAT
DUSP2 Forward TTGAGTGGTTTGGGATAGGTTAA GGGATAGGTTAAAGGGT
Reverse [Btn]AAAACRCAATCTAAACTAACCTAAAAACTT
CCND1 Forward [Btn]GGGYGGTTGGGTTTGTGTATTT CATATTTATCTTTTTATCTTCTACT
Reverse ACCACCCTACCCTAATTCT
ECRG4 Forward ATTTTGGGTAAGGAGGGTTAG GGGTAAAAGGGTTGT
Reverse [Btn]TACCATTTACCTCCTCTAAATTACCA
RUNX3 Forward [Btn]GGTTTTGGGAATTAGAGTTTAAGG AAAAAAAAATCAATTCCAACT
Reverse ACTAACATAACCCCRAAATAATACATCCTA
TP73 Forward AGTTAGTTGATAGAATTAAGGGAGATG ATGGGAAAAGYGAAAATGTTAATAA
Reverse [Btn]ATCTACACACRCCAAAAAACTAATATCCC
LCCR4 Forward TGGAAAGAGGAGTTTTTAGTTTATTTAAG AAATTTTAGGYGATGGTGAATTA
Reverse [Btn]ATTACCTACCACAAAAACTTCATAATAT
MAGEA2 Forward GATTTGYGTATTGGAGGTTAGAGGATA GTAAGAYGTYGAGGGAGGATTGA
Reverse [Btn]TAAAAAATCTTCCCCTACAAAATAATCCA
MGMT Forward TTTTTGGAGAGYGGTTGAGTTAGGT AGGTTATYGGTGATTGTAGTT
Reverse [Btn]CCAAACCAACAAAAACCCTATCA
NNAT Forward TGTAGGTTAGGGATTGGGGAGAA TTAAAGTAAAATTTAAAAGTAAGT
Reverse [Btn]TCCATCTTAACCCCCTTCCAA
TSPAN32 Forward GAGGTTTATAAAGTTTTTTTTTGGAGG GAGGTTTTAYGTGAGTGTGA
Reverse [Btn]CACCCTTTAAAATATCCTATAACAACTT
HPN Forward ATGAAATAAAGATTTTTGGATTTGATGTAT GTGAGTTTYGTTATTTTTTTTTTAT
Reverse [Btn]TAAATAACTTCACCTATAAACCCTCAAAT
JAK2 Forward [Btn]TTTTTTAGATAGTTATGGGATTGGTTTAT AATAAAAACRACAAAACAACAAACA
Reverse ACACTCCTTACCCTACTAAATTATATT
PAX 8 Forward GTGATTTAGGAGGATTTAGAGAATTTTATT ATTTTTTTGTATTTAGTTAGTTAA
Reverse [Btn]CTCTCCTCCTTCTAAAATTTATTCC
TDGF1 Forward ATTGGGGTTTGTTGTTGAAGAA TTTATTTTTTTTTTAAATTGTTATT
Reverse [Btn]AAACAACCAAAAAAAAACATTCATCTCC
RB1 Forward [Btn]TTGGGGTTGGTTTATTTATTTAGTTTTG TTACCCCTCCTCCCC
Reverse AACRAAAAACCCTTACCCCTCCTC
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Tumor samples were resected from 131 children diag-
nosed with NB between years 1996 and 2010 in Spanish
cooperative hospitals. Patients were included in different
national and European studies (LNESG I and II, INES,
EUNS, N-AR-99, N-II-92, and HR-NBL1) and carefullyselected in order to have all NB subtypes represented
(Table 1). Forty-eight NB tumor samples were used for
genome-wide promoter methylation analysis, and an add-
itional cohort of 83 tumor samples were used for validation.
Staging and risk stratification was established according to
International Neuroblastoma Risk Group (INRG) criteria
[2]. However, very low- and low-risk patients were joined
for the statistical analysis and were considered as low-risk
group. Samples were centrally reviewed and classified ac-
cording to the International Neuroblastoma Pathology
Committee (INPC) system [5,34]. Biological studies in-
cluded status of MYCN and 1p, both studied by FISH
Yáñez et al. Clinical Epigenetics  (2015) 7:16 Page 12 of 14according to ENQUA guidelines [35,36]. Parents or guard-
ians signed an informed consent statement for sample and
data management. The study was approved by the Hospital
La Fe Research Institute Ethical Committee.
Genome-wide promoter methylation profiling
Genomic DNA was extracted from frozen tumor tissues
by a standard proteinase K and phenol-chloroform ex-
traction protocol. The quality and quantity of the ex-
tracted DNA was measured by A260 spectrophotometric
absorbance. Genomic DNA bisulphite modification was
carried out following the manufacturer’s instructions
(Zymo Research). Promoter methylation analysis was per-
formed using the Infinium HumanMethylation27 BeadChip
(Illumina Inc., CA, USA) at the Spanish National Cancer
Center (CEGEN-CNIO, Madrid, Spain). The Infinium
HumanMethylation27 BeadChip allowed us to interro-
gate 27,578 highly informative CpG sites per sample,
located within the proximal gene promoter regions of
transcription. A file containing all CpG sites used in the
Illumina array HumanMethylation27 BeadChip can be
localized at http://support.illumina.com/array/array_kits/
infinium_humanmethylation27_beadchip_kit/downloads.
html. BeadStudio software (version 3, Illumina Inc, USA)
[37,38] was used to analyze the data. For each CpG
site, we calculated the beta-value (b-value), a quantitative
measure of DNA methylation levels ranging from 0 for
completely unmethylated to 1 for completely methylated
cytosines.
Bisulfite pyrosequencing
Promoter methylation data from the array was validated
by bisulfite pyrosequencing. Genomic DNA was bisulfite
modified using EZ DNA Methylation Gold Kit™ (Zymo
Research). A subsequent PCR amplification was performed
using biotinylated primers designed with the PyroMark
Assay Design 2.0 software, Qiagen (Table 6). The pyrose-
quencing and data analysis were performed in a PyroMark
Q24 System version 2.0.6 (Qiagen) following the manufac-
turer’s instructions.
Statistical analysis
The methylation status at each array probe was established
by analyzing the distribution of b-values for all samples
and CpG sites and transforming data into discrete values.
The cutoff values for hyper- and hypomethylation were
established using the minAS method [39] and considering
the bimodal distribution of b-values. Differential methyla-
tion analysis was done at the single CpG, CpG island, and
gene-centric levels. For the analysis of CpG island, in-
dividual probes were considered independent observation,
whereas the gene-level analysis simply counted the per-
centage of CpG and CpG island associated to each gene
that were declared significant. Differential methylationacross the NB subgroups was determined by either a pro-
portion test when several groups were compared or by
Fisher’s exact test when only two subgroups were in-
volved. Subgroups were established and compared based
on clinical and biological parameters such as age at first
diagnosis (younger vs. older than 18 months), MYCN sta-
tus (MYCN-amplified vs. non-amplified tumors), stage
(L1-L2 vs. M-MS), risk groups (low and intermediate vs.
high risk), relapse, and death (patients with events (relapse/
death) vs. patients without events). Nominal P values were
corrected for multiple tests using the Benjamini and
Hochberg FDR procedure [40].
Data distribution from pyrosequencing analysis was not
bimodal and varies among genes; therefore, variables were
analyzed as continuous. The relationship between the
methylation status and NB risk factors was evaluated using
a MANOVA test. A Cox elastic net analysis [41] was per-
formed to evaluate the influence on survival of gene pro-
moter methylation. This novel statistical analysis method is
especially suited for analyzing data with many variables
and few observations by performing variable selection.
This is done by penalizing predictors’ coefficients towards
zero according to their association with survival. Coeffi-
cients from variables with less influence on survival were
more penalized, dropped to zero, and excluded from the
predictive model.
For all the above-mentioned statistical tests, R software
(version 3.0.2) and package glmnet (version 1.9-5) were
used. For EFS analysis, time to event was defined as the
time from diagnosis until the time of first occurrence of
relapse, progression, or death. For OS, time to event was
defined as time until death or until last contact if the pa-
tient was alive. P values <0.05 were considered statistically
significant.
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pyrosequencing analysis in the validation cohort of patients.
Additional file 4: Correlation graphs between TDGF1 expression
and DNMT1 (A), DNMT3B (B) and DNMT3A (C) obtained at R2:
microarray analysis and visualization platform (http://r2.amc.nl)
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